文献速递肾癌与肾肿瘤

免疫检查点抑制剂或靶向治疗时代转移性肾细胞癌 upfront 减瘤性肾切除术:国际转移性肾细胞癌数据库联盟观察性研究

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
PubMed 文献 · Eur Urol · 2022-10-20

该回顾性观察研究利用国际转移性肾细胞癌数据库联盟,纳入4639例新发转移性肾细胞癌患者,其中靶向治疗4202例、免疫检查点抑制剂437例,分别有55%和54%在治疗前接受 upfront 减瘤性肾切除术。多变量分析显示,减瘤性肾切除术在免疫检查点抑制剂组(HR 0.61,95%CI 0.41-0.90,p=0.013)和靶向治疗组(HR 0.72,95%CI 0.67-0.78,p<0.001)均与更好的总生存相关,两组间无差异(交互作用 p=0.6)。

要点

  • 在靶向治疗或免疫检查点抑制剂治疗的新发转移性肾细胞癌患者中,upfront 减瘤性肾切除术与显著更好的总生存相关。
  • 免疫检查点抑制剂组 upfront 减瘤性肾切除术的 OS 获益 HR 为0.61(95%CI 0.41-0.90,p=0.013),靶向治疗组 HR 为0.72(95%CI 0.67-0.78,p<0.001)。
  • upfront 减瘤性肾切除术的 OS 获益在免疫检查点抑制剂与靶向治疗两组间无差异(交互作用 p=0.6)。

核心结论

  • 在经选择的接受免疫检查点抑制剂或靶向治疗的患者中,upfront 减瘤性肾切除术与显著的总生存获益相关,在免疫检查点抑制剂时代对经选择的患者仍有作用。

研究设计与样本

  • 利用国际转移性肾细胞癌数据库联盟,回顾性识别新发转移性肾细胞癌并接受免疫检查点抑制剂或靶向治疗的患者。
  • 共纳入4639例符合条件的转移性肾细胞癌患者,其中靶向治疗4202例、免疫检查点抑制剂437例。

主要发现

  • 靶向治疗组中有2326例(55%)在治疗开始前接受 upfront 减瘤性肾切除术,免疫检查点抑制剂组中有234例(54%)接受 upfront 减瘤性肾切除术。
  • 多变量分析中,减瘤性肾切除术在免疫检查点抑制剂治疗组与显著更好的 OS 相关(HR 0.61;95%CI 0.41-0.90,p=0.013)。
  • 多变量分析中,减瘤性肾切除术在靶向治疗组与显著更好的 OS 相关(HR 0.72;95%CI 0.67-0.78,p<0.001)。
  • 减瘤性肾切除术的 OS 获益在免疫检查点抑制剂与靶向治疗两组间无差异(交互作用 p=0.6)。

关键数值与推荐

  • upfront 减瘤性肾切除术在免疫检查点抑制剂组与 OS 改善相关,HR 0.61(95%CI 0.41-0.90,p=0.013)。
  • upfront 减瘤性肾切除术在靶向治疗组与 OS 改善相关,HR 0.72(95%CI 0.67-0.78,p<0.001)。
  • upfront 减瘤性肾切除术的 OS 获益在免疫检查点抑制剂与靶向治疗两组间无差异,交互作用 p=0.6。

临床怎么用

  • 原文结论认为 upfront 减瘤性肾切除术与显著 OS 获益相关,在免疫检查点抑制剂时代对经选择的患者仍有作用。

局限性

  • 局限性包括患者来自大型学术中心的选择偏倚以及研究的回顾性性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. OBJECTIVE: To evaluate the relationship between upfront CN and clinical outcomes in the setting of mRCC treated with immune checkpoint inhibitors or targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: Using the International Metastatic RCC Database Consortium, we retrospectively identified patients diagnosed with de novo mRCC treated with immune checkpoint inhibitors or targeted therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) was compared between the two groups using the Kaplan-Meier method and multivariable Cox regressions adjusting for known prognostic factors. RESULTS AND LIMITATIONS: We identified a total of 4639 eligible patients with mRCC. Among the 4202 patients treated with targeted therapy and 437 patients treated with immune checkpoint inhibitors, 2326 (55%) and 234 (54%) patients received upfront CN prior to treatment start. In multivariable analyses, CN was associated with significantly better OS in both the immune checkpoint inhibitor-treated (hazard ratio [HR]: 0.61; 95% confidence interval [CI], 0.41-0.90, p = 0.013) and the targeted therapy treatment (HR: 0.72; 95% CI, 0.67-0.78, p < 0.001) group. There was no difference in OS benefit of CN between the immune checkpoint inhibitor and targeted therapy treatment groups (interaction p = 0.6). Limitations include selection of patients from large academic centers and the retrospective nature of the study. CONCLUSIONS: Upfront CN is associated with a significant OS benefit in selected patients treated by either immune checkpoint inhibitors or targeted therapy, and still has a role in selected patients in the era of immune checkpoint inhibitors. PATIENT SUMMARY: Before effective systemic therapies were available for metastatic kidney cancer, surgical removal of the primary (kidney) tumor was the mainstay of treatment. The role of removing the primary tumor has recently been called into question given that more effective systemic therapies have become available. In this study, we find that removal of the primary kidney tumor still has a benefit for selected patients treated with highly effective modern systemic therapies, including targeted therapies and immune checkpoint inhibitors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bakouny Z, El Zarif T, Dudani S, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2022. PMID: 36272943. doi:10.1016/j.eururo.2022.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。